Pipeline J&J adds rare disease wAIHA to Imaavy’s potential uses PharmaphorumJohnson Johnson's 'Swiss army knife' drug Imaavy has shown efficacy in a pivotal trial involving patients with rare autoimmune disorder wAIHA.Rare DiseaseRead full story pharminent June 11, 2026 (Last updated: June 11, 2026) Pharmaphorum Johnson Johnson’s ‘Swiss army knife’ drug Imaavy has shown efficacy in a pivotal trial involving patients with rare autoimmune disorder wAIHA. Rare Disease Read full story Post navigation Previous: Novartis gets win for another Avidity muscular dystrophy AOCNext: Sky-high Parabilis, Kailera IPOs spur optimism–but only for derisked biotechs Related Stories Pipeline Beyond GLP1s: The race for nextgen obesity drugs starts in the preclinical models pharminent September 2, 2026 Pipeline Bausch + Lomb advances dry eye disease drug to Phase 3 despite mid-stage fail pharminent August 25, 2026 Pipeline Chasing Dupixent, a biotech aims to make better antibody drugs for eczema pharminent August 11, 2026